Systematic review with meta-analysis: The risk of major gastrointestinal bleeding with non-Vitamin K antagonist oral anticoagulants

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 11-12, 2015, Pages 1239-1249

  Caldeira, D ^a,b,c   Barra, M ^a   Ferreira, A ^a   Rocha, A ^a   Augusto, A ^a   Pinto, F J ^b   Costa, J ^a,b   Ferreira, J J ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; ODDS RATIO; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; GASTROINTESTINAL HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84945942160     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13412     Document Type: Review

References (60)

1. Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J,. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol 2015; 262: 516-22.
2. Majeed A, Hwang HG, Connolly SJ, et al,. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-32.
3. Piccini JP, Garg J, Patel MR, et al,. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014; 35: 1873-80.
4. Hylek EM, Held C, Alexander JH, et al,. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014; 63: 2141-7.
5. Eikelboom JW, Wallentin L, Connolly SJ, et al,. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al,. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
7. Patel MR, Mahaffey KW, Garg J, et al,. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
8. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET,. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145: 105-12.
9. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
10. Schulman S, Kearon C,. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
11. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W,. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-4.
12. Lane PW,. Meta-analysis of incidence of rare events. Stat Methods Med Res 2013; 22: 117-32.
13. Turner RM, Bird SM, Higgins JP,. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS ONE 2013; 8: e59202.
14. Kjaergard LL, Villumsen J, Gluud C,. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-9.
15. Zhang Z, Xu X, Ni H,. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Crit Care 2013; 17: R2.
16. Golder S, Loke Y,. Search strategies to identify information on adverse effects: a systematic review. J Med Libr Assoc 2009; 97: 84-92.
17. Loke YK, Price D, Herxheimer A,. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007; 7: 32.
18. Caldeira D, Barra M, Santos AT, et al,. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 2014; 100: 550-6.
19. Caldeira D, Costa J, Pinto FJ, Ferreira JJ,. The risk of infection with new oral anticoagulants: a meta-analysis. Int J Cardiol 2014; 172: 267-8.
20. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. John Wiley & Sons, 2011, 672 pp.
21. Deeks JJ,. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002; 21: 1575-600.
22. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
23. Sterne JA, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
24. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L,. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676-80.
25. Hori M, Matsumoto M, Tanahashi N, et al,. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J 2012; 76: 2104-11.
26. Connolly SJ, Eikelboo m J, Joyner C, et al,. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
27. Granger CB, Alexander JH, McMurray JJ, et al,. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
28. Giugliano RP, Ruff CT, Braunwald E, et al,. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
29. Agnelli G, Buller HR, Cohen A, et al,. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
30. Buller HR, Prins MH, Lensin AW, et al,. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
31. Bauersachs R, Berkowitz SD, Brenner B, et al,. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
32. Schulman S, Kearon C, Kakkar AK, et al,. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
33. Schulman S, Kakkar AK, Goldhaber SZ, et al,. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-72.
34. Buller HR, Decousus H, Grosso MA, et al,. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-15.
35. Schulman S, Kearon C, Kakkar AK, et al,. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-18.
36. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ,. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
37. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P,. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15.
38. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM,. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98.
39. Eriksson BI, Dahl OE, Rosencher N, et al,. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
40. Eriksson BI, Borris LC, Friedman RJ, et al,. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
41. Kakkar AK, Brenner B, Dahl OE, et al,. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9.
42. Lassen MR, Ageno W, Borris LC, et al,. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86.
43. Turpie AG, Lassen MR, Davidson BL, et al,. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-80.
44. Agnelli G, Buller HR, Cohen A, et al,. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
45. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W,. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
46. Hirsh J, Fuster V, Ansell J, Halperin JL,. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-711.
47. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W,. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450-8.
48. Beyer-Westendorf J, Pannach S,. Increase of gastrointestinal bleeding with new oral anticoagulants: problems of a meta-analysis. Gastroenterology 2013; 145: 1162-3.
49. Bytzer P, Connolly SJ, Yang S, et al,. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013; 11: 246-52. e1-5.
50. Toya Y, Nakamura S, Tomita K, et al,. Dabigatran-induced esophagitis: the prevalence and endoscopic characteristics. J Gastroenterol Hepatol 2015; doi: 10.1111/jgh.13024. [Epub ahead of print].
51. Chan EW, Lau WC, Leung WK, et al,. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015; 149: 586-95.
52. Goodman SG, Wojdyla DM, Piccini JP, et al,. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014; 63: 891-900.
53. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY,. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-6.
54. Sarrazin Vaughan MS, Jones M, Mazur A, Chrischilles E, Cram P,. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179-85.
55. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S,. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933-42.
56. Larsen TB, Rasmussen LH, Skjoth F, et al,. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-73.
57. Hernandez I, Baik SH, Pinera A, Zhang Y,. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015; 175: 18-24.
58. Staerk L, Gislason GH, Lip GY, et al,. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace 2015; 17: 1215-22.
59. Chang HY, Zhou M, Tang W, Alexander GC, Singh S,. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015; 350: h1585.
60. Abraham NS, Singh S, Alexander GC, et al,. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350: h1857.